Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc.

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.  
 
We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.  
 
With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Today we announced the successful manufacturing of CTx-1301 doses for both of our upcoming pivotal Phase 3 trials in pediatric and adolescents with #ADHD, with the fixed-dose study scheduled to begin the week of July 24.
 
Learn more: https://lnkd.in/exPF-XFW
$CING

Our Chairman and CEO, Shane Schaffer, will participate in a company discussion at the Maxim Group's Virtual Healthcare Conference tomorrow. 

To attend, register as an M-Vest member and reserve your seat here: https://lnkd.in/egF5_946
$CING #ADHD

Today we announced the completion of our Phase 3 trial evaluating the onset and duration of CTx-1301 in adults with #ADHD. Results are expected 3Q 2023.
 
Learn more: https://lnkd.in/ev_kre_W
$CING

Catch the live replay from Benzinga All Access this week to hear Shane Schaffer, $CING CEO, and Tim Moore, SVP of Biotech at Indegene, discuss our joint commercialization agreement and how we’ll leverage #AI to launch in the $20B #ADHD market: https://lnkd.in/e9pkPHhW

Our CEO, Shane Schaffer, joined fellow Kansas Citian and Royals broadcaster, Joel Goldberg, for an episode of his “Rounding The Bases” podcast. 

Listen to learn about our work in #ADHD and ambitions to become a powerhouse in the pharmaceutical industry – right from #KansasCity.

Today we announced first quarter 2023 financial results, including clinical and business updates on the Phase 3 program for our lead candidate, CTx-1301, for the treatment of #ADHD.

Read our press release to learn more: https://lnkd.in/eyzmJnkn
$CING

Our CEO, Shane Schaffer, stopped by Nasdaq’s Innovators with Jane King to discuss how we’re tackling unmet needs in #ADHD with our lead candidate CTx-1301 (dexmethylphenidate).

Watch the full video: https://lnkd.in/ej8aanrP
$CING

Today we announced the successful transfer of CTx-1301 proprietary Precision Timed Release™ manufacturing processes to Societal CDMO, keeping us on track to meet previously announced clinical timelines for our Phase 3 program in #ADHD. 

Learn more: https://lnkd.in/d36fuHaW
$CING Societal™ CDMO

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-11.55M -	-7.18M 37.78%	-20.71M 188.29%	-17.68M 14.65%
depreciation and amortization	178.91K -	666.03K 272.27%	708.32K 6.35%	394.01K 44.37%
deferred income tax			-16.26M -	-797.96K 95.09%
stock based compensation			12.78M -	800.80K 93.73%
change in working capital	1.88M -	-293.49K 115.59%	-3.21M 994.75%	598.62K 118.63%
accounts receivables	-71.83K -	-487.34K 578.42%	-1.86M 282.31%	1.25M 166.92%
inventory	-725.61K -			-1.25M -
accounts payables	1.70M -			791.00K -
other working capital	982.18K -	193.85K 80.26%	-1.35M 796.34%	-192.39K 85.75%
other non cash items	-48.05K -		16.26M -	797.96K 95.09%
net cash provided by operating activities	-9.53M -	-6.81M 28.55%	-10.43M 53.17%	-15.88M 52.24%	-15.04M 5.34%
investments in property plant and equipment	-1.02M -	-402.10K 60.42%	-814.74K 102.62%	-153.42K 81.17%
acquisitions net	-3.76M -	-17.92K 99.52%
purchases of investments	-1.55M -	-78 99.99%
sales maturities of investments	5.31M -	18K 99.66%		933 -
other investing activites	3.76M -	17.92K 99.52%		-165 -	-224K 135,657.58%
net cash used for investing activites	2.74M -	-384.17K 114.01%	-814.74K 112.07%	-152.65K 81.26%	-224K 46.74%
debt repayment	-725.61K -	-485.92K 33.03%	-936.59K 92.75%	-15.09K 98.39%
common stock issued		7.51M -	20.37M 171.43%	-85.92K 100.42%
common stock repurchased
dividends paid
other financing activites	6.87M -	954K 86.11%	7.10M 644.75%	5M 29.63%	9.96M 99.10%
net cash used provided by financing activities	6.14M -	7.97M 29.77%	26.54M 232.85%	4.90M 81.54%	9.96M 103.21%
effect of forex changes on cash
net change in cash	-644.74K -	779.20K 220.86%	15.30M 1,862.92%	-11.14M 172.81%	-5.30M 52.37%
cash at beginning of period	1.06M -	418.47K 60.64%	1.20M 186.20%	16.49M 1,277.07%
cash at end of period	418.47K -	1.20M 186.20%	16.49M 1,277.07%	5.36M 67.52%	-5.30M 199.02%
operating cash flow	-9.53M -	-6.81M 28.55%	-10.43M 53.17%	-15.88M 52.24%	-15.04M 5.34%
capital expenditure	-1.02M -	-402.10K 60.42%	-814.74K 102.62%	-153.42K 81.17%
free cash flow	-10.55M -	-7.21M 31.62%	-11.25M 55.93%	-16.04M 42.58%	-15.04M 6.24%

COM:CINGULATE

Cingulate Inc.

Last Close

0.37

26/07 20:00

Market Cap

4.76M

Beta: -

Volume Today

292.55K

Avg: -

Preview